Molecular targeted therapy of tumor hypoxia

Abstract

Li Shanshan, Xing Ligang, Sun Xiaorong. Molecular targeted therapy of tumor hypoxia[J]. Journal of International Oncology, 2014, 41(5): 327-331.

［1］ Wilson WR, Hay MP. Targeting hypoxia in cancer therapy［J］. Nat Rev Cancer, 2011, 11(6): 393-410. ［2］ Nishida CR, Lee M, de Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1［J］. Mol Pharmacol, 2010, 78(3):497-502. ［3］ Williams KJ, Albertella MR, Fitzpatrick B, et al. In vivo activation of the hypoxiatargeted cytotoxin AQ4N in human tumor xenografts［J］. Mol Cancer Ther, 2009, 8(12):3266-3275. ［4］ Papadopoulos KP, Goel S, Beeram M, et al. A phase 1 openlabel, accelerated doseescalation study of the hypoxiaactivated prodrug AQ4N in patients with advanced malignancies［J］. Clin Cancer Res, 2008, 14(21):7110-7115. ［5］ Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase Ⅰ study［J］. Ann Oncol, 2007, 18(6):1098-1103. ［6］ Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells［J］. Expert Opin Investig Drugs, 2009, 18 (1):7787. ［7］ Rischin D, Peters LJ, O′Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase Ⅲ trial of the transtasman radiation oncology group［J］. J Clin Oncol, 2010, 28(18):2989-2995. ［8］ Lim AM, Rischin D, Fisher R, et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase Ⅲ trial［J］. Clin Cancer Res, 2012, 18(1):301-307. ［9］ Sun JD, Liu Q, Wang J, et al. Selective tumor hypoxia targeting by hypoxiaactivated prodrug TH-302 inhibits tumor growth in preclinical models of cancer［J］. Clin Cancer Res, 2012, 18(3):758-770. ［10］ Ganjoo KN, Cranmer LD, Butrynski JE, et al. A phase Ⅰ study of the safety and pharmacokinetics of the hypoxiaactivated prodrug TH302 in combination with doxorubicin in patients with advanced soft tissue sarcoma［J］. Oncology, 2011, 80(1-2):50-56. ［11］ Borad MJ, Reddy S, Bahary N, et al. TH302+ gemcitabine vs gemcitabine in patients with untreated advanced pancreatic cancer［J］. Ann Oncol, 2012, 23(9S):S224-257. ［12］ Xia Y, Choi HK, Lee K, et al. Recent advances in hypoxiainducible factor (HIF)-1 inhibitors［J］. Eur J Med Chem, 2012, 49(3):24-40. ［13］ Wang R, Zhou S, Li S. Cancer therapeutic agents targeting hypoxiainducible factor-1［J］. Curr Med Chem, 2011, 18(21):3168-3189. ［14］ Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxiainducible factor1alpha, EZN2968, inhibits tumor cell growth［J］. Mol Cancer Ther, 2008, 7(11):35983608. ［15］ Patnaik A, Chiorean EG, Tolcher A, et al. EZN2968, a novel hypoxiainducible factor1α (HIF1a) messenger ribonucleic acid (mRNA) antagonist: results of a phase Ⅰ, pharmacokinetic (PK), doseescalation study of daily administration in patients (pts) with advanced malignancies［J］. J Clin Oncol, 2009, 27(15S):S2564. ［16］ Palayoor ST, Mitchell JB, Cerna D, et al. PX478, an inhibitor of hypoxiainducible factor1a, enhances radiosensitivity of prostate carcinoma cells［J］. Int J Cancer, 2008, 123(10):2430-2437. ［17］ Jacoby JJ, Erez B, Korshunova MV, et al. Treatment with HIF1 antagonist PX478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice［J］. J Thorac Oncol, 2010, 5(7):940-949. ［18］ Lee K, Kim HM. A novel approach to cancer therapy using PX478 as a HIF1α inhibitor［J］. Arch Pharm Res, 2011, 34(10):1583-1585. ［19］ Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer［J］. Nat Rev Cancer, 2008, 8(11):851-864. ［20］ Nagelkerke A, Bussink J, Mujcic H, et al. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3arm of the unfolded protein response［J］. Breast Cancer Res, 2013, 15(1):R2. ［21］ Papandreou I, Denko NC, Olson M, et al. Identi?cation of an Ire1alpha endonuclease speci?c inhibitor with cytotoxic activity against human multiple myeloma［J］. Blood, 2011, 117(4):1311-1314. ［22］ Turkington RC, Purcell C, James CR, et al. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma［J］. Invest New Drugs, 2013, 11. ［23］ Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma［J］. Br J Haematol, 2013, 160(5):649-659. ［24］ Advani SH. Targeting mTOR pathway: A new concept in cancer Therapy［J］. Indian J Med Paediatr Oncol, 2010, 31(4):132-136. ［25］ Nishikawa T, Takaoka M, Ohara T, et al. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancerbearing mice［J］. Cancer Biol Ther, 2013, 14(3):230-236. ［26］ Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma［J］. Oncologist, 2010, 15(4):428-435.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Molecular targeted therapy of tumor hypoxia

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments